Literature DB >> 9753622

Detection of mouse osteopontin by western blotting.

S R Rittling1, F Feng.   

Abstract

Several different antibodies to mouse and/or rat osteopontin have been developed, and some antisera raised against human osteopontin have been shown to react with mouse osteopontin. We have taken advantage of the lack of osteopontin protein in mice with a targeted disruption of the osteopontin gene to characterize the reactivity and the specificity of several of these antibodies with mouse osteopontin by Western blotting. Our results demonstrate that, with the exception of the rat monoclonal antibody MPIIIB10, which does not recognize mouse osteopontin on Western blots, all the tested reagents do react with mouse osteopontin, but their sensitivity varies widely, and in some cases there is significant cross-reactivity of the antibodies with other proteins found in mouse tissue extracts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753622     DOI: 10.1006/bbrc.1998.9306

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen.

Authors:  Ted S Gross; Katy A King; Natalia A Rabaia; Pranali Pathare; Sundar Srinivasan
Journal:  J Bone Miner Res       Date:  2004-10-11       Impact factor: 6.741

2.  Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta.

Authors:  Bradley Yates; Craig Zetterberg; Vaishali Rajeev; Michael Reiss; Susan R Rittling
Journal:  Exp Cell Res       Date:  2007-08-01       Impact factor: 3.905

3.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

4.  Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing.

Authors:  Yanping Chen; Susan R Rittling
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin.

Authors:  Rani Singh; Tommy Hui; Aritsune Matsui; Ziyad Allahem; Christopher D Johnston; Montserrat Ruiz-Torruella; Susan R Rittling
Journal:  Immunology       Date:  2016-10-07       Impact factor: 7.397

6.  Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy.

Authors:  Manolis Mavroidis; Yassemi Capetanaki
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

7.  Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.

Authors:  Jin-Hyung Lee; Atrayee Banerjee; Yoshi Ueno; Shashi K Ramaiah
Journal:  Toxicol Sci       Date:  2008-08-14       Impact factor: 4.849

8.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  Spatial survey of non-collagenous proteins in mineralizing and non-mineralizing vertebrate tissues ex vivo.

Authors:  Putu Ustriyana; Fabian Schulte; Farai Gombedza; Ana Gil-Bona; Sailaja Paruchuri; Felicitas B Bidlack; Markus Hardt; William J Landis; Nita Sahai
Journal:  Bone Rep       Date:  2021-02-10

10.  Osteopontin is required for full expression of the transformed phenotype by the ras oncogene.

Authors:  Y Wu; D T Denhardt; S R Rittling
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.